ライフサイエンスコーパス: decreased from @2 to

1 With CPG-directed care, intra-abdominal abscess rate decreased from 0.24 to 0.10 (adjusted risk ratio 0.44, 95% co

2 The rate of any adverse event decreased from 0.30 to 0.23 (adjusted risk ratio 0.82, 95% CI

3 QoL score decreased from 0.6 to 0.45 after 10 years.

4 Lethality by MDRPa similarly decreased from 3.6% to 0%.

5 The TAT for nevi decreased from 2 days to 1 day, for melanomas from 5 days to

6 In the 12-23 month age group, radiological pneumonia decreased from 15.3 to 10.9 cases per 1000 person-years (29%

7 tal hospital costs per patient (hospital accounting system) decreased from $16,466 to $10,528 (adjusted absolute differen

8 tem; the adjusted relative risk (ARR) of reporting problems decreased from 6 to 12 (ARR 0.87, 95% CI: 0.83-0.90), 12 to 2

9 ngestion, the grand mean +/- SEM plasma 3-HIB concentration decreased (from 35 +/- 2 to 14 +/- 1 micromol/L) and the gran

10 atients with health care-associated nosocomial endocarditis decreased (from 17.7% to 15.3%; APC, -1.0%; 95% CI, -1.4% to

11 Hospitalization rates of PCV13 serotype pneumonia decreased from 47.2 to 15.7 per 100000 admissions post PCV13.

12 We found that when the interstimulus interval decreased from 500 to 16 ms there was an approximate 79% redu

13 (Ptrend < .0001), while the proportion that were secondary decreased from 24% to 19% (Ptrend = .030).

14 Empirical antibiotic administration in the first 24 hours decreased from 5.0% to 2.6% (adjusted difference, -1.8; 95% C

15 Observed in-hospital mortality decreased from 5.7% to 2.9%, and 1-year mortality decreased f

16 omparatively, the TPC of the extract solution significantly decreased from 100% down to 20.8%, 11.2% and 8.6% at 10, 30 a

17 three times a day without adequate improvement (UPDRS score decreased from 23 to 20 points).

18 Uncertainty in simulated yield decreased from 38% to 20% between P1 and P2.

19 Resistance in S. aureus decreased from 2000 to 2014 by 0.8 antibiotics (0.7 to 0.8).

20 mortality decreased from 5.7% to 2.9%, and 1-year mortality decreased from 25.8% to 21.6%.

21 e USPSTF recommendation, median biopsy volume per urologist decreased from 29 to 21 (interquartile range [IQR}, 12-34; P

22 Hospitalization rates of PP decreased from 53.6 to 23.3 per 100000 admissions post PCV13

23 esion and striatal volumes were increased on day 3 and then decreased from days 7 to 28.

24 Similarly, major interstage complications decreased from 10% to 3% (P = 0.011).

25 Transesophageal echocardiography guidance decreased from 60.7% to 32.3% of cases, whereas more recent p

26 Warfarin use decreased from 52.4% to 34.8% (p for trend <0.01), and DOAC u

27 R0-resection rates decreased from 75% to 35% when changing the definition of R1

28 Mean total iron-binding capacity decreased from 501 to 389 mug/dL (ferrous sulfate) vs 506 to

29 ne period with the EOS calculator period, blood culture use decreased from 14.5% to 4.9% (adjusted difference, -7.7%; 95%

30 e EC-H2O2 system, Mn(II) removal efficiency increased as pH decreased from 6.5 to 4.5 and as pH increased from 6.5 to 8.5

31 arterly mean ventilator-associated event rate significantly decreased from 7.34 to 4.58 cases per 1,000 ventilator-days a

32 Over time, 90-day mortality decreased from initially 17% to 4% in 2015 (P = 0.002).

33 The median frequency of convulsive seizures per month decreased from 12.4 to 5.9 with cannabidiol, as compared with

34 roved, for example, fasting glucose and glycated hemoglobin decreased from 6.1 to 5.4 mmol/mol and 41.8% to 37.7%, respec

35 ICU length of stay decreased from 6.5 to 5.8 days in the immediate post period a

36 The ratio of neutral to acidic monosaccharides decreased from 6.7 to 5.7 as the extraction temperature was i

37 Intraoperative complication rates decreased from 8.4% to 5.0% (OR = 0.576, P = .043) comparing

38 From 1995 to 2015, mean age decreased from 66+/-14 to 63+/-14 years in patients with STEM

39 , the proportion of patients with native-valve endocarditis decreased (from 74.5% to 68.4%; APC, -0.7%; 95% CI, -0.9% to

40 <0.001), the rate of brain damage or nursing home admission decreased from 10.0% to 7.6% (P<0.001), and all-cause mortali

41 eased from 10.0% to 7.6% (P<0.001), and all-cause mortality decreased from 18.0% to 7.9% (P=0.002).

42 Thin-cap fibroatheroma prevalence decreased from 20.0% to 7.1% (p = 0.003).

43 The largest genera (Lactococcus) decreased from 33.03% to 7.94%, while the Akkermansia genera

44 e of adverse events for all individuals receiving denosumab decreased from 165.3 to 95.9 per 100 participant-years over t

45 In the endosperm, cornmeal and grits fumonisin levels decreased from 60 to 95%.

46 These oligosaccharides decreased from early lactation to almost undetectable levels

47 BAs in air decreased from south to north in the order Rao > northern Bal

48 ot in the propranolol group, memory vividness significantly decreased from pretest to posttest and follow-up after recall

49 roups, on the basis of whether DNA methylation increased or decreased from active disease to remission.

50 The ADIR and ADBR both exponentially decreased from the acute to the late periods (p < 0.0001).